Residual disease doesn’t tell the whole story—and defining “high risk” is rarely a black-and-white decision.
In this clip we analyze the delicate balance between treatment escalation and toxicity, the current limitations of ctDNA, and how “edge cases” often defy standard clinical trial protocols.
Early-Stage HER2+: Defining “High Risk” in Residual Disease
You may also like
Recommended Videos
